Clinical trial · Interventional
Continuous Erector Spinae Block for Post Analgesia in Pediatric Patients
Continuous Erector Spinae Plane Local Anesthetic Infusion for Postoperative Analgesia in Pediatric Patients Undergoing Nephrectomy: Randomized Controlled Study
NCT04613830CI-TRIAL-00063643completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate the analgesic efficacy of erector spinae plane block in pediatric cancer patients undergoing open nephrectomy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pediatric Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bupivacaine Hydrochloride | Drug | — | UNRESOLVED |
| Tramadol hydrochloride | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Erector spinae group
- description
- patient will be placed in a sitting position under complete aseptic condition and a cover sheath will be used for the ultrasound probe with an appropriate amount of lubricating gel applied on the probe, a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the L3 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae.
- interventionNames
- Drug: Bupivacaine Hydrochloride
- type
- PLACEBO_COMPARATOR
- label
- Opioid GROUP
- description
- Patient in group T will intravenously administrate dose of 1 mg/kg/8hr tramal ( opioid) to be increased upon patient needs up to 2mg/kg/6hr as rescue analgesic.
- interventionNames
- Drug: Tramadol hydrochloride
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 2 Years
- Maximum age
- 7 Years
Show eligibility criteria text
Inclusion Criteria: * Physical status ASA II. * Patients (age 2-7yrs) scheduled for open nephrectomy for malignant kidney tumors Exclusion Criteria: * History of psychological disorders. * Known sensitivity or contraindication to local anesthetics. * Localized infection at the site of block. * patients with coagulopathy or an (INR ≥ 2)
References
Publications (0)
Data not yet available
No reference posted for this study.